Pembrolizumab for Early Triple-Negative Breast Cancer
2020 · New England Journal of Medicine · 2,944 citations
https://doi.org/10.1056/nejmoa1910549
Y
Yeon Hee Park
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
392
Papers
16.5K
Citations
48
h-index
142
i10-index
Yeon Hee Park is an academic researcher from Samsung Medical Center. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Advanced Breast Cancer Therapies & Breast Cancer Treatment Studies. The author has an h-index of 48, co-authored 334 publications.
ORCID: 0000-0003-4156-9212Papers by this author
worksTrastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
2022 · New England Journal of Medicine · 2,396 citations
https://doi.org/10.1056/nejmoa2203690
Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer
2017 · Nature Communications · 1,023 citations
https://doi.org/10.1038/ncomms15081
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
2021 · The Lancet Oncology · 340 citations
https://doi.org/10.1016/s1470-2045(21)00034-6
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
2023 · The Lancet · 322 citations
https://doi.org/10.1016/s0140-6736(23)00725-0
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
2024 · New England Journal of Medicine · 310 citations
https://doi.org/10.1056/nejmoa2409932
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat